Clinical-stage biotech Moderna (NASDAQ:MRNA) has gained 16% on heavy postmarket volume after it posted postive Phase 1 data for its Cytomegalovirus vaccine mRNA-1647.
That comes after the third and final vaccination with the investigational treatment in Phase 1.
It also says the first participant was dosed in the Phase 2 dose-confirmation study.
The company says it’s actively preparing for a Phase 3 pivotal study to evaluate efficacy of mRNA-1647 against primary CMV infection.
It will discuss the data in a conference call Friday at 8 a.m. ET.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.